Ipamorelin

Ipamorelin is described as the mildest of GHRPs (Growth Hormone Releasing Peptides). It is discussed for stimulating growth hormone (GH) release without increasing appetite, cortisol, or prolactin.

Deeper Research Notes (Summary):
• Stimulates GH release by mimicking ghrelin, binding to GHS-R receptors in the brain, and inhibiting somatostatin (which suppresses GH production).
• Discussed as working on ghrelin receptors to promote GH release without increasing appetite (vs other GHRPs).
• GH support is discussed for muscle growth, fat metabolism, and bone health.
• Has shown potential for boosting insulin release from the pancreas (research discussion).

Cautions & Contraindications:
Cautions:
• May cause water retention, hunger, headaches, changes in blood sugar level, and joint pain
Contraindications:
• Individuals with active or a history of hormone-sensitive cancers
• Individuals with a history of severe low blood sugar levels

Reconstitution Options (Vial Format):
• 2 mg
• 5 mg
• 10 mg

Reconstitution (General Handling):
• Use sterile technique and sanitize the vial stopper before access.
• Add diluent slowly along the vial wall to minimize foaming.
• Gently swirl/roll until fully dissolved (avoid vigorous shaking).
• Choose a diluent volume that makes a 100–500 mcg dose easy to measure accurately.
• Store according to the product label/spec sheet and protect from light as applicable.

Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Molecular Formula: C₃₈H₄₉N₉O₅

Molecular Weight: 711.85 g mol^-1

Ipamorelin is a unique pentapeptide derived from GHRP-1, known for its selective release of growth hormone (GH) while leaving other hormone levels largely unaffected.

A comprehensive study has examined the pharmacological profile of Ipamorelin, revealing key insights into its behavior within the human body.

Significant increases in cortical BMC. Expanded femur and vertebra L6 volumes. Increased body weight, cortical bone area, and BMC. Notable improvements in dry defatted weight and bone volume after 12 weeks.

Ipamorelin positively influenced longitudinal bone growth rate (LGR) and body weight (BW) in rats.

A shorter median time to the first tolerated meal in the Ipamorelin group, Similar safety and efficacy profiles between Ipamorelin and placebo groups.

Fluid retention, joint pain, headaches, increased appetite, heightened response to insulin, affecting blood sugar levels.

Ipamorelin is a growth hormone secretagogue. It has selective and potential benefits in bone growth and postoperative ileus management. While some potential side effects have been suggested, further comprehensive research is needed to understand its safety and efficacy fully.

PubMed

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from https://case.edu/medicine/Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Case Western Reserve University School of Medicine

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as 'in glass' studies, are conducted outside of living organisms. It's important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.